

**Supplemental Table S3. Summary of Efficacy data in Ki-67 subpopulations at AFU1**

	IDFS			DRFS		
	Abemaciclib+ ET	ET alone	HR (95% CI)	Abemaciclib+ ET	ET alone	HR (95% CI)
<b>ITT Ki-67 high, N = 2498</b>						
Patients, N	1262	236		1262	1236	
Events, n	118	172	0.66	97	146	0.63
3-Year Rates, % (95% CI)	86.8 (83.7, 89.4)	80.8 (77.3, 83.9)	(0.52, 0.84)	88.3 (85.1, 90.8)	84.3 (81.1, 86.9)	(0.49, 0.83)
<b>Cohort 1 Ki-67 high, N = 2003</b>						
Patients, N	1017	986		1017	986	0.60
Events, n	104	158	0.63	85	135	(0.46, 0.79)
3-Year Rates, % (95% CI)	86.1 (82.8, 88.8)	79.0 (75.3, 82.3)	(0.49, 0.80)	87.8 (84.4, 90.5)	82.6 (79.2, 85.5)	
<b>Cohort 1 Ki-67 low, N = 1914</b>						
Patients, N	946	968		946	968	0.68
Events, n	62	86	0.70	50	73	(0.47, 0.98)
3-Year Rates, % (95% CI)	91.7 (89.1, 93.6)	87.2 (83.6, 90.0)	(0.51, 0.98)	93.1 (90.7, 94.9)	89.1 (85.8, 91.7)	